Baseline Levels of Dynamic CD4+ T Cell Adhesion to MAdCAM-1 Correlate With Clinical Response to Vedolizumab Treatment in Ulcerative Colitis: A Cohort Study

BMC Gastroenterology - United Kingdom
doi 10.1186/s12876-020-01253-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Vedolizumab Exposure Levels and Clinical Outcomes in Ulcerative Colitis: Determining the Potential for Dose Optimisation

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Author Response To: Comment On: Prospective Cohort Study of Appendicectomy for Treatment of Therapy‐refractory Ulcerative Colitis

British Journal of Surgery
Surgery
2019English

Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels Correlate With the Disease Activity of Ulcerative Colitis

Internal Medicine
Internal MedicineMedicine
2016English

Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2019English

A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated With Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2017English

New Keys to Maintenance Treatment in Ulcerative Colitis

Digestive Diseases
MedicineGastroenterology
2010English

CD4+ T-Cell Immunity in the Peripheral Blood Correlates With Response to Anti-Pd-1 Therapy

Cancer immunology research
Cancer ResearchImmunology
2019English

Transcript Levels of Toll-Like Receptors 5, 8 and 9 Correlate With Inflammatory Activity in Ulcerative Colitis

BMC Gastroenterology
MedicineGastroenterology
2011English

CD4 Effector T Cell Subsets in the Response to Influenza

Journal of Experimental Medicine
MedicineAllergyImmunology
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy